RedHill Biopharma (RDHL) Amortization (2016 - 2025)
Historic Amortization for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to $22.3 million.
- RedHill Biopharma's Amortization rose 496.4% to $22.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $22.3 million, marking a year-over-year increase of 496.4%. This contributed to the annual value of $22.2 million for FY2024, which is 1120.95% up from last year.
- Latest data reveals that RedHill Biopharma reported Amortization of $22.3 million as of Q2 2025, which was up 496.4% from $22.2 million recorded in Q4 2024.
- Over the past 5 years, RedHill Biopharma's Amortization peaked at $112.7 million during Q1 2021, and registered a low of -$5.4 million during Q2 2022.
- Over the past 5 years, RedHill Biopharma's median Amortization value was $20.6 million (recorded in 2023), while the average stood at $23.7 million.
- Per our database at Business Quant, RedHill Biopharma's Amortization tumbled by 16111.55% in 2022 and then skyrocketed by 78061.99% in 2023.
- Over the past 5 years, RedHill Biopharma's Amortization (Quarter) stood at $13.7 million in 2021, then plummeted by 121.36% to -$2.9 million in 2022, then surged by 780.62% to $20.0 million in 2023, then grew by 11.21% to $22.2 million in 2024, then rose by 0.29% to $22.3 million in 2025.
- Its Amortization stands at $22.3 million for Q2 2025, versus $22.2 million for Q4 2024 and $21.2 million for Q2 2024.